ERTS Wealth Advisors LLC Sells 3,515 Shares of Pfizer Inc. (NYSE:PFE)

ERTS Wealth Advisors LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 27.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 9,097 shares of the biopharmaceutical company’s stock after selling 3,515 shares during the quarter. ERTS Wealth Advisors LLC’s holdings in Pfizer were worth $262,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Moneta Group Investment Advisors LLC lifted its position in shares of Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the last quarter. Norges Bank bought a new stake in shares of Pfizer during the 4th quarter worth $3,150,472,000. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares during the last quarter. Morgan Stanley lifted its position in shares of Pfizer by 10.3% during the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after buying an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Pfizer during the 1st quarter worth $311,238,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on PFE. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. UBS Group dropped their target price on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. Barclays dropped their target price on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Finally, Truist Financial dropped their target price on Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $36.88.

View Our Latest Report on PFE

Pfizer Trading Down 1.2 %

Shares of PFE stock opened at $27.23 on Thursday. The stock has a 50-day moving average of $27.41 and a 200-day moving average of $29.25. Pfizer Inc. has a 1-year low of $25.61 and a 1-year high of $42.22. The stock has a market cap of $154.19 billion, a price-to-earnings ratio of 75.64, a PEG ratio of 1.23 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFEGet Free Report) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter last year, the firm posted $1.14 earnings per share. The firm’s revenue was down 41.3% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.